Evidence map›Paper›PMID 38192626›Full record

ArticleFrontiers in oncology2023

The MANGO study: a prospective investigation of oxygen enhanced and blood-oxygen level dependent MRI as imaging biomarkers of hypoxia in glioblastoma.

Caterina Brighi, David E J Waddington, Paul J Keall, Jeremy Booth, Kieran O'Brien, Shona Silvester, Jonathon Parkinson, Marco Mueller, Jackie Yim, Dale L Bailey and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Caterina BrighiImage X Institute, Sydney School of Health Sciences, The University of Sydney, Sydney, NSW, Australia.
David E J WaddingtonImage X Institute, Sydney School of Health Sciences, The University of Sydney, Sydney, NSW, Australia.
Paul J KeallImage X Institute, Sydney School of Health Sciences, The University of Sydney, Sydney, NSW, Australia.
Jeremy BoothDepartment of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
Kieran O'BrienSiemens Healthcare Pty Ltd, Brisbane, QLD, Australia.
Shona SilvesterImage X Institute, Sydney School of Health Sciences, The University of Sydney, Sydney, NSW, Australia.
Jonathon ParkinsonDepartment of Neurosurgery, Royal North Shore Hospital, Sydney, NSW, Australia.
Marco MuellerSiemens Healthcare Pty Ltd, Brisbane, QLD, Australia.
Jackie YimDepartment of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
Dale L BaileyDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW, Australia.
Michael BackDepartment of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
James DrummondDepartment of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
The University of Sydney · AURoyal North Shore Hospital · AUSiemens (Australia) · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma (GBM) is the most aggressive type of brain cancer, with a 5-year survival rate of ~5% and most tumours recurring locally within months of first-line treatment. Hypoxia is associated with worse clinical outcomes in GBM, as it leads to localized resistance to radiotherapy and subsequent tumour recurrence. Current standard of care treatment does not account for tumour hypoxia, due to the challenges of mapping tumour hypoxia in routine clinical practice. In this clinical study, we aim to investigate the role of oxygen enhanced (OE) and blood-oxygen level dependent (BOLD) MRI as non-invasive imaging biomarkers of hypoxia in GBM, and to evaluate their potential role in dose-painting radiotherapy planning and treatment response assessment. Methods: The primary endpoint is to evaluate the quantitative and spatial correlation between OE and BOLD MRI measurements and [ Discussion: MANGO (Magnetic resonance imaging of hypoxia for radiation treatment guidance in glioblastoma multiforme) is a diagnostic/prognostic study investigating the role of imaging biomarkers of hypoxia in GBM management. The study will generate a large amount of longitudinal multimodal MRI and PET imaging data that could be used to unveil dynamic changes in tumour physiology that currently limit treatment efficacy, thereby providing a means to develop more effective and personalised treatments.

Indexed as

dose paintingglioblastomahypoxia imagingmagnetic resonance imagingradiotherapytreatment response assessment

Identifiers

PMID38192626
PMCPMC10773871
OpenAlexW4390078593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.